Novel therapies against aggressive and recurrent epithelial cancers by molecular targeting tumor- and metastasis-initiating cells and their progenies

Anti-Cancer Agents in Medicinal Chemistry

Volumn 10, Issue 2, 2010, Pages 137-151

  Mimeault, Murielle ^a   Batra, Surinder K ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Combination cancer therapy; Epithelial cancers; Pancreatic cancer stem progenitor cells; Prostate cancer stem progenitor cells; Targeted therapy; Treatment resistance

Indexed keywords

ABC TRANSPORTER; ALDEHYDE DEHYDROGENASE; ANTISENSE OLIGODEOXYNUCLEOTIDE; BETA CATENIN; BMI1 PROTEIN; CHEMOKINE RECEPTOR CXCR4; CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; GEFITINIB; GLYCOPROTEIN P; GROWTH FACTOR; HERMES ANTIGEN; HYALURONIC ACID; INTERLEUKIN 6; MONOCLONAL ANTIBODY; NOTCH RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BCL 2; PROTEIN P53; RETINOBLASTOMA PROTEIN; SONIC HEDGEHOG PROTEIN; STEM CELL FACTOR; STROMAL CELL DERIVED FACTOR 1; TELOMERASE REVERSE TRANSCRIPTASE; TEMOZOLOMIDE; TRASTUZUMAB; UNINDEXED DRUG; WNT PROTEIN;

BRAIN CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER RISK; CANCER STEM CELL; CANCER SURGERY; CARCINOGENESIS; CELL AGING; CELL TRANSFORMATION; COLON CANCER; COLORECTAL CANCER; DNA METHYLATION; DNA REPAIR; ENZYME INHIBITION; EPITHELIUM TUMOR; EXTRACELLULAR MATRIX; FIBROSIS; GENE AMPLIFICATION; GENE DELETION; GENE MUTATION; HORMONAL THERAPY; HUMAN; INFLAMMATION; INTRAHEPATIC BILE DUCT; KARYOTYPE; MELANOMA; METASTASIS; MULTIDRUG RESISTANCE; NEURAL STEM CELL; OXIDATIVE STRESS; PANCREAS CANCER; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; TELOMERE; TUMOR SUPPRESSOR GENE; XENOGRAFT;

EID: 77950793274     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152010790909353     Document Type: Review

References (241)

1. Hope, K.J.; Jin, L.; Dick, J.E. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in selfrenewal capacity. Nat. Immunol., 2004, 5(7), 738-743.
2. Matsui, W.; Wang, Q.; Barber, J.P.; Brennan, S.; Smith, B.D.; Borrello, I.; McNiece, I.; Lin, L.; Ambinder, R.F.; Peacock, C.; Watkins, D.N.; Huff, C.A.; Jones, R.J. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res., 2008, 68(1), 190-197.
3. Fang, D.; Nguyen, T.K.; Leishear, K.; Finko, R.; Kulp, A.N.; Hotz, S.; Van Belle, P.A.; Xu, X.; Elder, D.E.; Herlyn, M.A. Tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res., 2005, 65(20), 9328-9337.
4. Galli, R.; Binda, E.; Orfanelli, U.; Cipelletti, B.; Gritti, A.; De Vitis S.; Fiocco, R.; Foroni, C.; Dimeco, F.; Vescovi, A. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res., 2004, 64(19) 7011-7021.
5. Singh, S.K.; Hawkins, C.; Clarke, I.D.; Squire, J.A.; Bayani, J.; Hide, T. Henkelman, R.M.; Cusimano, M.D.; Dirks, P.B. Identification of human brain tumour initiating cells. Nature, 2004, 432(7015), 396-401.
6. Al-Hajj, M.; Wicha, M.S.; Ito-Hernandez, A.; Morrison, S.J.; Clarke, M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA, 2003, 100(7), 3983-3988. (Pubitemid 36418143)
7. Kim, C.F.; Jackson, E.L.; Woolfenden, A.E.; Lawrence, S.; Babar, I.; Vogel, S.; Crowley, D.; Bronson, R.T.; Jacks, T. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell, 2005, 121(6), 823-835.
8. Eramo, A.; Lotti, F.; Sette, G.; Pilozzi, E.; Biffoni, M.; Di Virgilio A.; Conticello, C.; Ruco, L.; Peschle, C.; De Maria R. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ., 2008, 15(3), 504-514.
9. Wright, M.H.; Calcagno, A.M.; Salcido, C.D.; Carlson, M.D.; Ambudkar, S.V.; Varticovski, L. Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res., 2008, 10(1), R10.
10. Ginestier, C.; Hur, M.H.; Charafe-Jauffret, E.; Monville, F.; Dutcher, J.; Brown, M.; Jacquemier, J.; Viens, P.; Kleer, C.G.; Liu, S.; Schott, A.; Hayes, D.; Birnbaum, D.; Wicha, M.S.; Dontu, G. ALDH1 Is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell. Stem Cell, 2007, 1(5), 555-567.
11. Yang, Z.F.; Ho, D.W.; Ng, M.N.; Lau, C.K.; Yu, W.C.; Ngai, P.; Chu P.W.; Lam, C.T.; Poon, R.T.; Fan, S.T. Significance of CD90(+) cancer stem cells in human liver cancer. Cancer Cell, 2008, 13(2), 153-166.
12. Hermann, P.C.; Huber, S.L.; Herrler, T.; Aicher, A.; Ellwart, J.W.; Guba, M.; Bruns, C.J.; Heeschen, C. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell. Stem Cell, 2007, 1(3), 313-323.
13. Zhang, S.; Balch, C.; Chan, M.W.; Lai, H.C.; Matei, D.; Schilder, J.M.; Yan, P.S.; Huang, T.H.; Nephew, K.P. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res., 2008, 68(11), 4311-4320.
14. Liu, G.; Yuan, X.; Zeng, Z.; Tunici, P.; Ng, H.; Abdulkadir, I.R.; Lu, L.; Irvin, D.; Black, K.L.; Yu, J.S. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol. Cancer, 2006, 5, 67.
15. Schatton, T.; Murphy, G.F.; Frank, N.Y.; Yamaura, K.; Waaga-Gasser, A.M.; Gasser, M.; Zhan, Q.; Jordan, S.; Duncan, L.M.; Weishaupt, C.; Fuhlbrigge, R.C.; Kupper, T.S.; Sayegh, M.H.; Frank, M.H. Identification of cells initiating human melanomas. Nature, 2008, 451(7176) 345-349.
16. Maitland, N.J.; Bryce, S.D.; Stower, M.J.; Collins, A.T. Prostate cancer stem cells: a target for new therapies. Ernst. Schering. Found. Symp. Proc., 2006, 5, 155-179.
17. Mimeault, M.; Hauke, R.; Mehta, P.P.; Batra, S.K. Recent advances on cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers. J. Mol. Cell. Med., 2007, 11(5), 981-1011.
18. Shi, G.M.; Xu, Y.; Fan, J.; Zhou, J.; Yang, X.R.; Qiu, S.J.; Liao, Y.; Wu, W.Z.; Ji, Y.; Ke, A.W.; Ding, Z.B.; He, Y.Z.; Wu, B.; Yang, G.H.; Qin, W.Z.; Zhang, W.; Zhu, J.; Min, Z.H.; Wu, Z.Q. Identification of side population cells in human hepatocellular carcinoma cell lines with stepwise metastatic potentials. J. Cancer Res. Clin. Oncol., 2008, 134(11), 1155-1163.
19. Ricci-Vitiani, L.; Lombardi, D.G.; Pilozzi, E.; Biffoni, M.; Todaro, M.; Peschle, C.; De Maria R. Identification and expansion of human colon-cancer-initiating cells. Nature, 2007, 445(7123), 111-115.
20. Huang, D.; Gao, Q.; Guo, L.; Zhang, C.; Wei, J.; Li, H.; Jing, W.J.; Han, X.; Shi, Y.; Shih, H.L. Isolation and identification of cancer stem-like cells in esophageal carcinoma cell lines. Stem Cells Dev., 2009, 18(3), 465-473.
21. Huang, Q.; Zhang, Q.B.; Dong, J.; Wu, Y.Y.; Shen, Y.T.; Zhao, Y.D.; Zhu, Y.D.; Diao, Y.; Wang, A.D.; Lan, Q. Glioma stem cells are more aggressive in recurrent tumors with malignant progression than in the primary tumor, and both can be maintained long-term in vitro. BMC Cancer, 2008, 8, 304.
22. Alvero, A.B.; Chen, R.; Fu, H.H.; Montagna, M.; Schwartz, P.E.; Rutherford, T.; Silasi, D.A.; Steffensen, K.D.; Waldstrom, M.; Visintin, I.; Mor, G. Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle, 2009, 8(1), 158-166.
23. Baba, T.; Convery, P.A.; Matsumura, N.; Whitaker, R.S.; Kondoh, E.; Perry, T.; Huang, Z.; Bentley, R.C.; Mori, S.; Fujii, S.; Marks, J.R.; Berchuck, A.; Murphy, S.K. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene, 2009, 28(2), 209-218.
24. Todaro, M.; Alea, M.P.; Di Stefano, A.B.; Cammareri, P.; Vermeulen, L.; Iovino, F.; Tripodo, C.; Russo, A.; Gulotta, G.; Medema, J.-P.; Stassi, G. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell. Stem Cell, 2007, 1(4), 389-402.
25. Haraguchi, N.; Utsunomiya, T.; Inoue, H.; Tanaka, F.; Mimori, K.; Barnard, G.F.; Mori, M. Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells, 2006, 24(3), 506-513.
26. Hirschmann-Jax, C.; Foster, A.E.; Wulf, G.G.; Nuchtern, J.G.; Jax, T.W.; Gobel, U.; Goodell, M.A.; Brenner, M.K. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc. Natl. Acad. Sci. USA, 2004, 101(39), 14228-14233.
27. Wang, J.; Guo, L.P.; Chen, L.Z.; Zeng, Y.X.; Lu, S.H. Identification of cancer stem cell-like side population cells in human nasopharyngeal carcinoma cell line. Cancer Res., 2007, 67(8), 3716-3724.
28. Bapat, S.A.; Mali, A.M.; Koppikar, C.B.; Kurrey, N.K. Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res., 2005, 65(8), 3025-3029.
29. Chiba, T.; Miyagi, S.; Saraya, A.; Aoki, R.; Seki, A.; Morita, Y.; Yonemitsu, Y.; Yokosuka, O.; Taniguchi, H.; Nakauchi, H.; Iwama, A. The polycomb gene product BMI1 contributes to the maintenance of tumor-initiating side population cells in hepatocellular carcinoma. Cancer Res., 2008, 68(19), 7742-7749.
30. Nicolis, S.K. Cancer stem cells and "stemness" genes in neurooncology. Neurobiol. Dis., 2007, 25(2), 217-229.
31. Sato, M.; Shames, D.S.; Gazdar, A.F.; Minna, J.D. A translational view of the molecular pathogenesis of lung cancer. J. Thorac. Oncol., 2007, 2(4), 327-343.
32. Gray-Schopfer, V.; Wellbrock, C.; Marais, R. Melanoma biology and new targeted therapy. Nature, 2007, 445(7130), 851-857.
33. Ma, S.; Lee, T.K.; Zheng, B.J.; Chan, K.W.; Guan, X.Y. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene, 2008, 27(12), 1749-1758.
34. Rich, J.N. Cancer stem cells in radiation resistance. Cancer Res., 2007, 67(19), 8980-8984.
35. Brabletz, T.; Jung, A.; Spaderna, S.; Hlubek, F.; Kirchner, T. Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat. Rev. Cancer, 2005, 5(9), 744-749.
36. Tso, C.L.; Shintaku, P.; Chen, J.; Liu, Q.; Liu, J.; Chen, Z.; Yoshimoto, K.; Mischel, P.S.; Cloughesy, T.F.; Liau, L.M.; Nelson, S.F. Primary glioblastomas express mesenchymal stem-like properties. Mol. Cancer Res., 2006, 4(9), 607-619.
37. Bao, S.; Wu, Q., McLendon, R.E.; Hao, Y.; Shi, Q.; Hjelmeland, A.B.; Dewhirst, M.W.; Bigner, D.D.; Rich, J.N. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature, 2006, 444(7120), 756-760.
38. Sengupta, A.; Banerjee, D.; Chandra, S.; Banerji, S.K.; Ghosh, R.; Roy, R.; Banerjee, S. Deregulation and cross talk among Sonic hedgehog, Wnt, Hox and Notch signaling in chronic myeloid leukemia progression. Leukemia, 2007, 21, 949-955.
39. Liu, S.; Dontu, G.; Mantle, I.D.; Patel, S.; Ahn, N.S.; Jackson, K.W.; Suri, P.; Wicha, M.S. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res., 2006, 66(12), 6063-6071.
40. Li, L.; Neaves, W.B. Normal stem cells and cancer stem cells: the niche matters. Cancer Res., 2006, 66(9), 4553-4557.
41. Katoh, M. Networking of WNT, FGF, Notch, BMP, and Hedgehog signaling pathways during carcinogenesis. Stem Cell Rev., 2007, 3(1), 30-38.
42. Mimeault, M.; Batra, S.K. Recent insights into the molecular mechanisms involved in aging and the malignant transformation of adult stem/progenitor cells and their therapeutic implications. Ageing Res. Rev., 2009, 8(2), 94-112.
43. Onoue, T.; Uchida, D.; Begum, N.M.; Tomizuka, Y.; Yoshida, H.; Sato, M. Epithelial-mesenchymal transition induced by the stromal cell-derived factor-1/CXCR4 system in oral squamous cell carcinoma cells. Int. J. Oncol., 2006, 29(5), 1133-1138.
44. Glinsky, G.V. "Stemness" genomics law governs clinical behavior of human cancer: implications for decision making in disease management. J. Clin. Oncol., 2008, 26(17), 2846-2853.
45. Mimeault, M.; Batra, S.K. Interplay of distinct growth factors during epithelial-mesenchymal transition of cancer progenitor cells and molecular targeting as novel cancer therapies. Ann. Oncol., 2007, 18(10), 1605-1619.
46. Mimeault, M.; Batra, S.K. Functions of tumorigenic and migrating cancer progenitor cells in cancer progression and metastasis and their therapeutic implications. Cancer Metastasis Rev., 2007, 26(1), 203-214.
47. Mimeault, M.; Batra, S.K. Targeting of cancer stem/progenitor cells plus stem cell-based therapies: the ultimate hope for treating and curing aggressive and recurrent cancers. Panminerva Med., 2008, 50(1), 3-18.
48. Mimeault, M.; Mehta, P.P.; Hauke, R.; Batra, S.K. Functions of normal and malignant prostatic stem/progenitor cells in tissue regeneration and cancer progression and novel targeting therapies. Endocr. Rev., 2008, 29(2), 234-252.
49. Mimeault, M.; Batra, S.K. Recent progress on normal and malignant pancreatic stem/progenitor cell research: therapeutic implications for the treatment of type 1 or 2 diabetes mellitus and aggressive pancreatic cancer. Gut, 2008, 57(10), 1456-1468.
50. Moustakas, A.; Heldin, C.H. Dynamic control of TGF-beta signaling and its links to the cytoskeleton. FEBS Lett., 2008, 582(14), 2051-2065.
51. Katoh, M.; Katoh, M. Integrative genomic analyses of CXCR4: transcriptional regulation of CXCR4 based on TGFbeta, Nodal, Activin signaling and POU5F1, FOXA2, FOXC2, FOXH1, SOX17, and GFI1 transcription factors. Int. J. Oncol., 2010, 36(2), 415-420.
52. Das, B.; Tsuchida, R.; Malkin, D.; Koren, G.; Baruchel, S.; Yeger, H. Hypoxia enhances tumor stemness by increasing the invasive and tumorigenic side population fraction. Stem Cells, 2008, 26(7), 1818-1830.
53. Thiery, J.P.; Sleeman, J.P. Complex networks orchestrate epithelial-mesenchymal transitions. Nat. Rev. Mol. Cell Biol., 2006, 7(2), 131-142.
54. Zhou, B.P.; Hung, M.C. Wnt, hedgehog and snail: sister pathways that control by GSK-3beta and beta-Trcp in the regulation of metastasis. Cell Cycle, 2006, 4(6), 772-776.
55. Turley, E.A.; Veiseh, M.; Radisky, D.C.; Bissell, M.J. Mechanisms of disease: epithelial-mesenchymal transition--does cellular plasticity fuel neoplastic progression? Nat. Clin. Pract. Oncol., 2008, 5(5), 280-290.
56. Wang, X.; Belguise, K.; Kersual, N.; Kirsch, K.H.; Mineva, N.D.; Galtier, F.; Chalbos, D.; Sonenshein, G.E. Oestrogen signalling inhibits invasive phenotype by repressing RelB and its target BCL2. Nat. Cell Biol., 2007, 9(4), 470-478.
57. Spaderna, S.; Schmalhofer, O.; Hlubek, F.; Jung, A.; Kirchner, T.; Brabletz, T. Epithelial-mesenchymal and mesenchymal-epithelial transitions during cancer progression. Verh. Dtsch. Ges. Pathol., 2007, 91, 21-28.
58. Shipitsin, M.; Campbell, L.L.; Argani, P.; Weremowicz, S.; Bloushtain-Qimron, N.; Yao, J.; Nikolskaya, T.; Serebryiskaya, T.; Beroukhim, R.; Hu, M.; Halushka, M.K.; Sukumar, S.; Parker, L.M.; Anderson, K.S.; Harris, L.N.; Garber, J.E.; Richardson, A.L.; Schnitt, S.J.; Nikolsky, Y.; Gelman, R.S.; Polyak, K. Molecular definition of breast tumor heterogeneity. Cancer Cell, 2007, 11(3), 259-273.
59. Storci, G.; Sansone, P.; Trere, D.; Tavolari, S.; Taffurelli, M.; Ceccarelli, C.; Guarnieri, T.; Paterini, P.; Pariali, M.; Montanaro, L.; Santini, D.; Chieco, P.; Bonafe, M. The basal-like breast carcinoma phenotype is regulated by SLUG gene expression. J. Pathol., 2008, 214(1), 25-37.
60. Shah, A.N.; Summy, J.M.; Zhang, J.; Park, S.I.; Parikh, N.U.; Gallick, G.E. Development and characterization of gemcitabineresistant pancreatic tumor cells. Ann. Surg. Oncol., 2007, 14(12), 3629-3637.
61. Moustakas, A.; Heldin, C.H. Signaling networks guiding epithelialmesenchymal transitions during embryogenesis and cancer progression. Cancer Sci., 2007, 98(10), 1512-1520.
62. Sarkar, F.H.; Li, Y.; Wang, Z.; Kong, D. NF-kappaB signaling pathway and its therapeutic implications in human diseases. Int. Rev. Immunol., 2008, 27(5), 293-319.
63. Ponti, D.; Costa, A.; Zaffaroni, N.; Pratesi, G.; Petrangolini, G.; Coradini, D.; Pilotti, S.; Pierotti, M.A.; Daidone, M.G. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res., 2005, 65(13), 5506-5511.
64. Patrawala, L.; Calhoun, T.; Schneider-Broussard, R.; Li, H.; Bhatia, B.; Tang, S.; Reilly, J.G.; Chandra, D.; Zhou, J.; Claypool, K.; Coghlan, L.; Tang, D.G. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene, 2006, 25(12), 1696-1708.
65. Patrawala, L.; Calhoun-Davis, T.; Schneider-Broussard, R.; Tang, D.G. Hierarchical organization of prostate cancer cells in xenograft tumors: The CD44+{alpha}2{beta}1+ cell population is enriched in tumor-initiating cells. Cancer Res., 2007, 67(14), 6796-6805.
66. Wei, C.; Guomin, W.; Yujun, L.; Ruizhe, Q. Cancer stem-like cells in human prostate carcinoma cells DU145: The seeds of the cell line? Cancer Biol. Ther., 2007, 6(5), 763-768.
67. Yang, Z.F.; Ngai, P.; Ho, D.W.; Yu, W.C.; Ng, M.N.; Lau, C.K.; Li, M.L.; Tam, K.H.; Lam, C.T.; Poon, R.T.; Fan, S.T. Identification of local and circulating cancer stem cells in human liver cancer. Hepatology, 2008, 47(3), 919-928. (Pubitemid 351449683)
68. Fillmore, C.M.; Kuperwasser, C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res., 2008, 10(2), R25.
69. Quintana, E.; Shackleton, M.; Sabel, M.S.; Fullen, D.R.; Johnson, T.M.; Morrison, S.J. Efficient tumour formation by single human melanoma cells. Nature, 2008, 456(7222), 593-598.
70. Shmelkov, S.V.; Butler, J.M.; Hooper, A.T.; Hormigo, A.; Kushner, J.; Milde, T.; St Clair R.; Baljevic, M.; White, I.; Jin, D.K.; Chadburn, A.; Murphy, A.J.; Valenzuela, D.M.; Gale, N.W.; Thurston, G.; Yancopoulos, G.D.; D'Angelica, M.; Kemeny, N.; Lyden, D.; Rafii, S. CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J. Clin. Invest., 2008, 118(6), 2111-2120.
71. Aktas, B.; Tewes, M.; Fehm, T.; Hauch, S.; Kimmig, R.; Kasimir-Bauer, S. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res., 2009, 11(4), R46.
72. Balic, M.; Lin, H.; Young, L.; Hawes, D.; Giuliano, A.; McNamara, G.; Datar, R.H.; Cote, R.J. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin. Cancer Res. 2006, 12(19), 5615-5621.
73. Liu, R.; Wang, X.; Chen, G.Y.; Dalerba, P.; Gurney, A.; Hoey, T.; Sherlock, G.; Lewicki, J.; Shedden, K.; Clarke, M.F. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N. Engl. J. Med., 2007, 356(3), 217-226.
74. Zhang, X.; Komaki, R.; Wang, L.; Fang, B.; Chang, J.Y. Treatment of radioresistant stem-like esophageal cancer cells by an apoptotic gene-armed, telomerase-specific oncolytic adenovirus. Clin. Cancer Res., 2008, 14(9), 2813-2823.
75. Sung, J.M.; Cho, H.J.; Yi, H.; Lee, C.H.; Kim, H.S.; Kim, D.K.; bd El-Aty, A.M.; Kim, J.S.; Landowski, C.P.; Hediger, M.A.; Shin, H.C. Characterization of a stem cell population in lung cancer A549 cells. Biochem. Biophys. Res. Commun., 2008, 371(1), 163-167.
76. Friel, A.M.; Sergent, P.A.; Patnaude, C.; Szotek, P.P.; Oliva, E.; Scadden, D.T.; Seiden, M.V.; Foster, R.; Rueda, B.R. Functional analyses of the cancer stem cell-like properties of human endometrial tumor initiating cells. Cell Cycle, 2008, 7(2), 242-249.
77. Loebinger, M.R.; Giangreco, A.; Groot, K.R.; Prichard, L.; Allen, K.; Simpson, C.; Bazley, L.; Navani, N.; Tibrewal, S.; Davies, D.; Janes, S.M. Squamous cell cancers contain a side population of stem-like cells that are made chemosensitive by ABC transporter blockade. Br. J. Cancer, 2008, 98(2), 380-387.
78. Mimeault, M.; Hauke, R.; Batra, S.K. Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies. Clin. Pharmacol. Ther., 2008, 83(5), 673-691.
79. Levina, V.; Marrangoni, A.M.; DeMarco, R.; Gorelik, E.; Lokshin, A..E. Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS ONE, 2008, 3(8), e3077.
80. Phillips, T.M.; McBride, W.H.; Pajonk, F. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J. Natl. Cancer Inst., 2006, 98(24), 1777-1785.
81. Johannessen, T.C.; Bjerkvig, R.; Tysnes, B.B. DNA repair and cancer stem-like cells - Potential partners in glioma drug resistance? Cancer Treat. Rev., 2008, 34(6), 558-567.
82. Chen, Y.C.; Hsu, H.S.; Chen, Y.W.; Tsai, T.H.; How, C.K.; Wang, C.Y.; Hung, S.C.; Chang, Y.L.; Tsai, M.L.; Lee, Y.Y.; Ku, H.H.; Chiou, S.H. Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. PLoS ONE, 2008, 3(7), e2637.
83. Dylla, S.J., Beviglia, L.; Park, I.K.; Chartier, C.; Raval, J.; Ngan, L.; Pickell, K.; Aguilar, J.; Lazetic, S.; Smith-Berdan, S.; Clarke, M.F.; Hoey, T.; Lewicki, J. Gurney, A.L. Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS ONE, 2008, 3(6), e2428.
84. Fukuda, K.; Saikawa, Y.; Ohashi, M.; Kumagai, K.; Kitajima, M.; Okano, H.; Matsuzaki, Y.; Kitagawa, Y. Tumor initiating potential of side population cells in human gastric cancer. Int. J. Oncol. 2009, 34(5), 1201-1207.
85. Vaish, M. Mismatch repair deficiencies transforming stem cells into cancer stem cells and therapeutic implications. Mol. Cancer, 2007, 6, 26.
86. Catassi, A.; Servent, D.; Paleari, L.; Cesario, A.; Russo, P. Multiple roles of nicotine on cell proliferation and inhibition of apoptosis: implications on lung carcinogenesis. Mutat. Res., 2008, 659(3), 221-231.
87. Nijhof, J.G.; van Pelt C.; Mulder, A.A., Mitchell, D.L.; Mullenders, L.H.; de Gruijl, F.R. Epidermal stem and progenitor cells in murine epidermis accumulate UV damage despite NER proficiency. Carcinogenesis, 2007, 28(4), 792-800.
88. Aubert, G.; Lansdorp, P.M. Telomeres and aging. Physiol. Rev., 2008, 88(2), 557-579.
89. Widera, D.; Kaus, A.; Kaltschmidt, C.; Kaltschmidt, B. Neural stem cells, inflammation and NF-kappaB: basic principle of maintenance and repair or origin of brain tumours? J. Cell. Mol. Med., 2008, 12(2), 459-470.
90. Gumucio, D.L.; Fagoonee, S.; Qiao, X.T.; Liebert, M.; Merchant, J.L.; Altruda, F.; Rizzetto, M.; Pellicano, R. Tissue stem cells and cancer stem cells: potential implications for gastric cancer. Panminerva Med., 2008, 50(1), 65-71.
91. Friedman, S.L. Mechanisms of hepatic fibrogenesis. Gastroenterology, 2008, 134(6), 1655-1669.
92. Sharpless, N.E.; DePinho, R.A. How stem cells age and why this makes us grow old. Nat. Rev. Mol. Cell Biol., 2007, 8(9), 703-713.
93. Griffero, F.; Daga, A.; Marubbi, D.; Capra, M.C.; Melotti, A.; Pattarozzi, A.; Gatti, M.; Bajetto, A.; Porcile, C.; Barbieri, F.; Favoni, R.E.; Lo, C.M.; Zona, G.; Spaziante, R.; Florio, T.; Corte, G. Different response of human glioma tumor-initiating cells to EGFR kinase inhibitors. J. Biol. Chem., 2009, 284(11), 7138-7148.
94. Gonda, T.A.; Tu, S.; Wang, T.C. Chronic inflammation, the tumor microenvironment and carcinogenesis. Cell Cycle, 2009, 8(13), 2005-2013.
95. Riethdorf, S.; Wikman, H.; Pantel, K. Review: Biological relevance of disseminated tumor cells in cancer patients. Int. J. Cancer, 2008, 123(9), 1991-2006.
96. Zhou, J.; Wulfkuhle, J.; Zhang, H.; Gu, P.; Yang, Y.; Deng, J.; Margolick, J.B.; Liotta, L.A.; Petricoin, E. III; Zhang, Y. Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stemlike cells is required for viability and maintenance. Proc. Natl. Acad. Sci. USA, 2007, 104(41), 16158-16163.
97. Mimeault, M.; Batra, S.K. New promising drug targets in cancerand metastasis-initiating cells. Drug Discov. Today, 2010, (in press).
98. Dean, M.; Fojo, T.; Bates, S. Tumour stem cells and drug resistance. Nat. Rev. Cancer, 2005, 5(4), 275-284.
99. Ho, M.M.; Ng, A.V.; Lam, S.; Hung, J.Y. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res., 2007, 67(10), 4827-4833.
100. Salmaggi, A.; Boiardi, A.; Gelati, M.; Russo, A.; Calatozzolo, C.; Ciusani, E.; Sciacca, F.L.; Ottolina, A.; Parati, E.A.; La Porta C.; Alessandri, G.; Marras, C.; Croci, D.; De Rossi, M. Glioblastomaderived tumorospheres identify a population of tumor stem-like cells with angiogenic potential and enhanced multidrug resistance phenotype. Glia, 2006, 54(8), 850-860.
101. Frank, N.Y.; Margaryan, A.; Huang, Y.; Schatton, T.; Waaga-Gasser, A.M.; Gasser, M.; Sayegh, M.H.; Sadee, W.; Frank, M.H. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res., 2005, 65(10), 4320-4333.
102. Kang, M.K.; Kang, S.K. Tumorigenesis of chemotherapeutic drugresistant cancer stem-like cells in brain glioma. Stem Cells Dev., 2007, 16(5), 837-847.
103. Mimeault, M.; Batra, S.K. Recent advances on the development of novel anti-cancer drugs targeting cancer stem/progenitor cells. Drug Dev. Res., 2008, 69(7), 415-430.
104. Shervington, A.; Lu, C. Expression of multidrug resistance genes in normal and cancer stem cells. Cancer Invest., 2008, 26(5), 535-542.
105. Xu, J.X.; Morii, E.; Liu, Y.; Nakamichi, N.; Ikeda, J.; Kimura, H.; Aozasa, K. High tolerance to apoptotic stimuli induced by serum depletion and ceramide in side-population cells: high expression of CD55 as a novel character for side-population. Exp. Cell Res., 2007, 313(9), 1877-1885.
106. Birnie, R.; Bryce, S.D.; Roome, C.; Dussupt, V.; Droop, A.; Lang, S.H.; Berry, P.A.; Hyde, C.F.; Lewis, J.L.; Stower, M.J.; Maitland, N.J.; Collins, A.T. Gene expression profiling of human prostate cancer stem cells reveals a pro-inflammatory phenotype and the importance of extracellular matrix interactions. Genome Biol., 2008, 9(5), R83.
107. Li, T.; Su, Y.; Mei, Y.; Leng, Q.; Leng, B.; Liu, Z.; Stass, S.A.; Jiang, F. ALDH1A1 is a marker for malignant prostate stem cells and predictor of prostate cancer patients' outcome. Lab. Invest., 2010, 90(2), 234-244.
108. Rappa, G.; Fodstad, O.; Lorico, A. The stem cell-associated antigen CD133 (Prominin-1) is a molecular therapeutic target for metastatic melanoma. Stem Cells, 2008, 26(12), 3008-3017.
109. Yao, J.; Zhang, T.; Ren, J.; Yu, M.; Wu, G. Effect of CD133/prominin-1 antisense oligodeoxynucleotide on in vitro growth characteristics of Huh-7 human hepatocarcinoma cells and U251 human glioma cells. Oncol. Rep., 2009, 22(4), 781-787.
110. Xu, M.; Yuan, Y.; Xia, Y.; Achilefu, S. Monoclonal antibody CC188 binds a carbohydrate epitope expressed on the surface of both colorectal cancer stem cells and their differentiated progeny. Clin. Cancer Res., 2008, 14(22), 7461-7469.
111. Misra, S.; Toole, B.P.; Ghatak, S. Hyaluronan constitutively regulates activation of multiple receptor tyrosine kinases in epithelial and carcinoma cells. J. Biol. Chem., 2006, 281(46), 34936-34941.
112. Ghatak, S.; Misra, S.; Toole, B.P. Hyaluronan oligosaccharides inhibit anchorage-independent growth of tumor cells by suppressing the phosphoinositide 3-kinase/Akt cell survival pathway. J. Biol. Chem., 2002, 277(41), 38013-38020.
113. Bourguignon, L.Y.; Peyrollier, K.; Xia, W.; Gilad, E. Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells. J. Biol. Chem., 2008, 283(25), 17635-17651.
114. Gilg, A.G.; Tye, S.L.; Tolliver, L.B.; Wheeler, W.G.; Visconti, R.P.; Duncan, J.D.; Kostova, F.V.; Bolds, L.N.; Toole, B.P.; Maria, B.L. Targeting hyaluronan interactions in malignant gliomas and their drug-resistant multipotent progenitors. Clin. Cancer Res., 2008, 14(6), 1804-1813.
115. Mimeault, M.; Johansson, S.L.; Henichart, J.P.; Depreux, P.; Batra, S.K. Cytotoxic effects induced by docetaxel, gefitinib and cyclopamine on side population and non-side population cell fractions from human invasive prostate cancer cells. Mol. Cancer Ther., 2010, (in press).
116. Feldmann, G.; Dhara, S.; Fendrich, V.; Bedja, D.; Beaty, R.; Mullendore, M.; Karikari, C.; Alvarez, H.; Iacobuzio-Donahue, C.; Jimeno, A.; Gabrielson, K.L.; Matsui, W.; Maitra, A. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res., 2007, 67(5), 2187-2196.
117. Feldmann, G.; Fendrich, V.; McGovern,K.; Bedja, D.; Bisht, S.; Alvarez, H.; Koorstra, J.B.; Habbe, N.; Karikari, C.; Mullendore, M.; Gabrielson, K.L.; Sharma, R.; Matsui, W.; Maitra, A. An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer. Mol. Cancer Ther., 2008, 7(9), 2725-2735.
118. Karhadkar, S.S.; Bova, G.S.; Abdallah, N.; Dhara, S.; Gardner, D.; Maitra, A.; Isaacs, J.T.; Berman, D.M.; Beachy, P.A. Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature, 2004, 431(7009), 707-712.
119. Villanueva, A.; Newell, P.; Chiang, D.Y.; Friedman, S.L.; Llovet, J.M. Genomics and signaling pathways in hepatocellular carcinoma. Semin. Liver Dis., 2007, 27(1), 55-76.
120. Medicherla, S.; Li, L.; Ma, J.Y.; Kapoun, A.M.; Gaspar, N.J.; Liu, Y.W.; Mangadu, R.; O'Young, G.; Protter, A.A.; Schreiner, G.F.; Wong, D.H.; Higgins, L.S. Antitumor activity of TGF-beta inhibitor is dependent on the microenvironment. Anticancer Res., 2007, 27(6B), 4149-4157.
121. Rosa, D.D.; Ismael, G.; Lago, L.D.; Awada, A. Molecular-targeted therapies: lessons from years of clinical development. Cancer Treat. Rev., 2008, 34(1), 61-80.
122. Schmidt, C. Lapatinib study supports cancer stem cell hypothesis, encourages industry research. J. Natl. Cancer Inst., 2008, 100(10), 694-695.
123. Agelopoulos, K.; Buerger, H.; Brandt, B. Allelic imbalances of the egfr gene as key events in breast cancer progression--the concept of committed progenitor cells. Curr. Cancer Drug Targets, 2008, 8(5), 431-445.
124. Yamashita, T.; Ji, J.; Budhu, A.; Forgues, M.; Yang, W.; Wang, H.Y.; Jia, H.; Ye, Q.; Qin, L.X.; Wauthier, E.; Reid, L.M.; Minato, H.; Honda, M.; Kaneko, S.; Tang, Z.Y.; Wang, X.W. EpCAMPositive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology, 2008, 136(3), 1012-1024.
125. Magnifico, A.; Albano, L.; Campaner, S.; Delia, D.; Castiglioni, F.; Gasparini, P.; Sozzi, G.; Fontanella, E.; Menard, S.; Tagliabue, E. Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab. Clin. Cancer Res., 2009, 15(6), 2010-2021.
126. Tanaka, H.; Nakamura, M.; Kameda, C.; Kubo, M.; Sato, N.; Kuroki, S.; Tanaka, M.; Katano, M. The Hedgehog signaling pathway plays an essential role in maintaining the CD44+CD24-/low subpopulation and the side population of breast cancer cells. Anticancer Res., 2009, 29(6), 2147-2157.
127. Rubin, L.L.; de Sauvage, F.J. Targeting the Hedgehog pathway in cancer. Nat. Rev. Drug Discov. 2006, 5(12), 1026-1033.
128. Clement, V.; Sanchez, P.; de Tribolet N.; Radovanovic, I.; Altaba, A. HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr. Biol., 2007, 17(2), 165-172.
129. Jimeno, A.; Feldmann, G.; Suarez-Gauthier, A.; Rasheed, Z.; Solomon, A.; Zou, G.M.; Rubio-Viqueira, B.; Garcia-Garcia, E.; Lopez-Rios, F.; Matsui, W.; Maitra, A.; Hidalgo, M. A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development. Mol. Cancer Ther., 2009, 8(2), 310-314.
130. Mimeault, M.; Hauke, R.; Batra, S.K. Stem cells -- A revolution in therapeutics--Recent advances on the stem cell biology and their therapeutic applications in regenerative medicine and cancer therapies. Clin. Pharmacol. Ther., 2007, 82(3), 252-264.
131. Mimeault, M.; Batra, S.K. Stem Cell Applications in Disease Research: Recent Advances on Stem Cell and Cancer Stem Cell Biology and their Therapeutic Implications. In Progress in Stem Cell Applications; Faraday, A.V. and Dyer, J.T., Eds.; NOVA Publisher, New York: 2008; pp. 57-98.
132. Mimeault, M.; Batra, S.K. Recent advances on the significance of stem cells in tissue regeneration and cancer therapies. Stem Cells, 2006, 24(11), 2319-2345.
133. Strizzi, L.; Bianco, C.; Normanno, N.; Salomon, D. Cripto-1: a multifunctional modulator during embryogenesis and oncogenesis. Oncogene, 2005, 24(37), 5731-5741.
134. Hu, X.F.; Xing, P.X. Cripto as a target for cancer immunotherapy. Expert Opin. Ther. Targets, 2005, 9(2), 383-394.
135. Ugel, S.; Scarselli, E.; Iezzi, M.; Mennuni, C.; Pannellini, T.; Calvaruso, F.; Cipriani, B.; De, P.R.; Ricci-Vitiani, L.; Peranzoni, E.; Musiani, P.; Zanovello, P.; Bronte, V. Autoimmune B cell lymphopenia following successful adoptive therapy with telomerasespecific T lymphocytes. Blood, 2009, [Epub ahead of Print].
136. Sabisz, M.; Skladanowski, A. Cancer stem cells and escape from drug-induced premature senescence in human lung tumor cells: implications for drug resistance and in vitro drug screening models. Cell Cycle, 2009, 8(19), 3208-3217.
137. Chen, J.S.; Pardo, F.S.; Wang-Rodriguez, J.; Chu, T.S.; Lopez, J.P.; Aguilera, J.; Altuna, X.; Weisman, R.A.; Ongkeko, W.M. EGFR regulates the side population in head and neck squamous cell carcinoma. Laryngoscope, 2006, 116(3), 401-406.
138. Hu, C.; Li, H.; Li, J.; Zhu, Z.; Yin, S.; Hao, X.; Yao, M.; Zheng, S.; Gu, J. Analysis of ABCG2 expression and side population identifies intrinsic drug efflux in the HCC cell line MHCC-97L and its modulation by Akt signaling. Carcinogenesis, 2008, 29(12), 2289-2297.
139. Sims-Mourtada, J.; Izzo, J.G.; Ajani, J.; Chao, K.S. Sonic Hedgehog promotes multiple drug resistance by regulation of drug transport. Oncogene, 2007, 26, 5674-5679.
140. Zhou, J.; Zhang, H.; Gu, P.; Bai, J.; Margolick, J.B.; Zhang, Y. NFkappaB pathway inhibitors preferentially inhibit breast cancer stem-like cells. Breast Cancer Res. Treat., 2007, 29, 909-912.
141. Li, Y.M.; Song, S.T.; Jiang, Z.F.; Zhang, Q.; Su, C.Q.; Liao, G.Q.; Qu, Y.M.; Xie, G.Q.; Li, M.Y.; Ge, F.J.; Qian, Q.J. Telomerasespecific oncolytic virotherapy for human hepatocellular carcinoma. World J. Gastroenterol., 2008, 14(8), 1274-1279.
142. Filatenkov, A.; Muller, A.M.; Tseng, W.W.; jbakhsh-Jones, S.; Winer, D.; Luong, R.; Shizuru, J.A.; Engleman, E.G.; Strober, S. Ineffective vaccination against solid tumors can be enhanced by hematopoietic cell transplantation. J. Immunol., 2009, 183(11), 7196-7203.
143. Mine, T.; Matsueda, S.; Li, Y.; Tokumitsu, H.; Gao, H.; Danes, C.; Wong, K.K.; Wang, X.; Ferrone, S.; Ioannides, C.G. Breast cancer cells expressing stem cell markers CD44+ CD24 lo are eliminated by Numb-1 peptide-activated T cells. Cancer Immunol. Immunother., 2009, 58(8), 1185-1194.
144. Todaro, M.; D'Asaro, M.; Caccamo, N.; Iovino, F.; Francipane, M.G.; Meraviglia, S.; Orlando, V.; La M endola, C.; Gulotta, G.; Salerno, A.; Dieli,
145. Sell, S. Stem cell origin of cancer and differentiation therapy. Crit. Rev. Oncol. Hematol., 2004, 51(1), 1-28.
146. Massard, C.; Deutsch, E.; Soria, J.C. Tumour stem cell-targeted treatment: elimination or differentiation. Ann. Oncol., 2006, 17(11), 1620-1624.
147. Perabo, F.G.; Muller, S.C. New agents for treatment of advanced transitional cell carcinoma. Ann. Oncol., 2006, 18(5), 835-843.
148. Moserle, L.; Indraccolo, S.; Ghisi, M.; Frasson, C.; Fortunato, E.; Canevari, S.; Miotti, S.; Tosello, V.; Zamarchi, R.; Corradin, A.; Minuzzo, S.; Rossi, E.; Basso, G.; Amadori, A. The side population of ovarian cancer cells is a primary target of IFN-alpha antitumor effects. Cancer Res., 2008, 68(14), 5658-5668.
149. Huang, C.; Zhang, X.M.; Tavaluc, R.T.; Hart, L.S.; Dicker, D.T.; Wang, W.; El-Deiry, W.S. The combination of 5-Fluorouracil plus p53 pathway restoration is associated with depletion of p53-deficient or mutant p53-expressing putative colon cancer stem cells. Cancer Biol. Ther., 2009, 8(22), 2186-2193.
150. Ji, Q.; Hao, X.; Meng, Y.; Zhang, M.; Desano, J.; Fan, D.; Xu, L. Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer, 2008, 8, 266.
151. Yang, W.; Yan, H.X.; Chen, L.; Liu, Q.; He, Y.Q.; Yu, L.X.; Zhang, S.H.; Huang, D.D.; Tang, L.; Kong, X.N.; Chen, C.; Liu, S.Q.; Wu, M.C.; Wang, H.Y. Wnt/beta-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells. Cancer Res., 2008, 68(11), 4287-4295.
152. Frank, R.T.; Edmiston, M.; Kendall, S.E.; Najbauer, J.; Cheung, C.W.; Kassa, T.; Metz, M.Z.; Kim, S.U.; Glackin, C.A.; Wu, A.M.; Yazaki, P.J.; Aboody, K.S. Neural stem cells as a novel platform for tumor-specific delivery of therapeutic antibodies. PLoS ONE, 2009, 4(12), e8314.
153. Zischek, C.; Niess, H.; Ischenko, I.; Conrad, C.; Huss, R.; Jauch, K.W.; Nelson, P.J.; Bruns, C. Targeting tumor stroma using engineered mesenchymal stem cells reduces the growth of pancreatic carcinoma. Ann. Surg., 2009, 250(5), 747-753.
154. Vlashi, E.; Kim, K.; Lagadec, C.; Donna, L.D.; McDonald, J.T.; Eghbali, M.; Sayre, J.W.; Stefani, E.; McBride, W.; Pajonk, F. In vivo imaging, tracking, and targeting of cancer stem cells. J. Natl. Cancer Inst., 2009, 101(5), 350-359.
155. Rafii, S.; Lyden, D.; Benezra, R.; Hattori, K.; Heissig, B. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat. Rev. Cancer, 2002, 2(11), 826-835.
156. Davidoff, A.M.; Ng, C.Y.; Brown, P.; Leary, M.A.; Spurbeck, W.W.; Zhou, J.; Horwitz, E.; Vanin, E.F.; Nienhuis, A.W. Bone marrow-derived cells contribute to tumor neovasculature and, when modified to express an angiogenesis inhibitor, can restrict tumor growth in mice. Clin. Cancer Res., 2001, 7(9), 2870-2879.
157. Loebinger, M.R.; Eddaoudi, A.; Davies, D.; Janes, S.M. Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. Cancer Res., 2009, 69(10), 4134-4142.
158. Mimeault, M.; Batra, S.K. Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies. Carcinogenesis, 2006, 27, 1-22.
159. De Marzo, A.M.; DeWeese, T.L.; Platz, E.A.; Meeker, A.K.; Nakayama, M.; Epstein, J.I.; Isaacs, W.B.; Nelson, W.G. Pathological and molecular mechanisms of prostate carcinogenesis: implications for diagnosis, detection, prevention, and treatment. J. Cell Biochem., 2004, 91(3), 459-477.
160. Litvinov, I.V.; Vander Griend, D.J.; Xu, Y.; Antony, L.; Dalrymple, S.L.; Isaacs, J.T. Low-calcium serum-free defined medium selects for growth of normal prostatic epithelial stem cells. Cancer Res., 2006, 66(17), 8598-8607.
161. Chen, B.Y.; Liu, J.Y.; Chang, H.H.; Chang, C.P.; Lo, W.Y.; Kuo, W.H.; Yang, C.R.; Lin, D.P. Hedgehog is involved in prostate basal cell hyperplasia formation and its progressing towards tumorigenesis. Biochem. Biophys. Res. Commun., 2007, 357(4), 1084-1089.
162. Nikitin, A.Y.; Matoso, A.; Roy-Burman, P. Prostate stem cells and cancer. Histol. Histopathol., 2007, 22(9), 1043-1049.
163. Collins, A.T.; Berry, P.A.; Hyde, C.; Stower, M.J.; Maitland, N.J. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res., 2005, 65(23), 10946-10951.
164. Collins, A.T.; Maitland, N.J. Prostate cancer stem cells. Eur. J. Cancer, 2006, 42(12), 1213-1218.
165. Sharifi, N.; Kawasaki, B.T.; Hurt, E.M.; Farrar, W.L. Stem cells in prostate cancer: Resolving the castrate-resistant conundrum and implications for hormonal therapy. Cancer Biol. Ther., 2006, 5(8), 901-906.
166. Kasper, S.; Cookson, M.S. Mechanisms leading to the development of hormone-resistant prostate cancer. Urol. Clin. North Am., 2006, 33(2), 201-210.
167. Lam, J.S.; Reiter, R.E. Stem cells in prostate and prostate cancer development. Urol. Oncol., 2006, 24(2), 131-140.
168. Miki, J.; Furusato, B.; Li, H.; Gu, Y.; Takahashi, H.; Egawa, S.; Sesterhenn, I.A.; McLeod, D.G.; Srivastava, S.; Rhim, J.S. Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumorderived human prostate epithelial cell lines and in prostate cancer specimens. Cancer Res., 2007, 67(7), 3153-3161.
169. Rowehl, R.A.; Crawford, H.; Dufour, A.; Ju, J.; Botchkina, G.I. Genomic analysis of prostate cancer stem cells isolated from a highly metastatic cell line. Cancer Genomics, Proteomics, 2008, 5(6), 301-310.
170. Guzman-Ramirez, N.; Voller, M.; Wetterwald, A.; Germann, M.; Cross, N.A.; Rentsch, C.A.; Schalken, J.; Thalmann, G.N.; Cecchini, M.G. In vitro propagation and characterization of neoplastic stem/progenitor-like cells from human prostate cancer tissue. Prostate, 2009, 69(15), 1683-1693.
171. Blum, R.; Gupta, R.; Burger, P.E.; Ontiveros, C.S.; Salm, S.N.; Xiong, X.; Kamb, A.; Wesche, H.; Marshall, L.; Cutler, G.; Wang, X.; Zavadil, J.; Moscatelli, D.; Wilson, E.L. Molecular signatures of prostate stem cells reveal novel signaling pathways and provide insights into prostate cancer. PLoS ONE, 2009, 4(5), e5722.
172. Cunha, G.R.; Ricke, W.; Thomson, A.; Marker, P.C.; Risbridger, G.; Hayward, S.W.; Wang, Y.Z.; Donjacour, A.A.; Kurita, T. Hormonal, cellular, and molecular regulation of normal and neoplastic prostatic development. J. Steroid Biochem. Mol. Biol., 2004, 92(4), 221-236.
173. Ao, M.; Franco, O.E.; Park, D.; Raman, D.; Williams, K.; Hayward, S.W. Cross-talk between paracrine-acting cytokine and chemokine pathways promotes malignancy in benign human prostatic epithelium. Cancer Res., 2007, 67(9), 4244-4253.
174. Chung, L.W.; Baseman, A.; Assikis, V.; Zhau, H.E. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. J. Urol., 2005, 173(1), 10-20.
175. Rizzo, S.; Attard, G.; Hudson, D.L. Prostate epithelial stem cells. Cell Prolif., 2005, 38(6), 363-374.
176. Brown, M.D.; Gilmore, P.E.; Hart, C.A.; Samuel, J.D.; Ramani, V.A.; George, N.J.; Clarke, N.W. Characterization of benign and malignant prostate epithelial Hoechst 33342 side populations. Prostate, 2007, 67(13), 1384-1396.
177. Guzman-Ramirez, N.; Voller, M.; Wetterwald, A.; Germann, M.; Cross, N.A.; Rentsch, C.A.; Schalken, J.; Thalmann, G.N.; Cecchini, M.G. In vitro propagation and characterization of neoplastic stem/progenitor-like cells from human prostate cancer tissue. Prostate, 2009, 69(15), 1683-1693.
178. Heer, R.; Robson, C.N.; Shenton, B.K.; Leung, H.Y. The role of androgen in determining differentiation and regulation of androgen receptor expression in the human prostatic epithelium transient amplifying population. J. Cell Physiol., 2007, 212(3), 572-578.
179. Simon, R.A.; di Sant'agnese, P.A.; Huang, L.S.; Xu, H.; Yao, J.L.; Yang, Q.; Liang, S.; Liu, J.; Yu, R.; Cheng, L.; Oh, W.K.; Palapattu, G.S.; Wei, J.; Huang, J. CD44 expression is a feature of prostatic small cell carcinoma and distinguishes it from its mimickers. Hum. Pathol., 2009, 40(2), 252-258.
180. Alam, T.N.; O'Hare, M.J.; Laczko, I.; Freeman, A.; Al-Beidh, F.; Masters, J.R.; Hudson, D.L. Differential expression of CD44 during human prostate epithelial cell differentiation. J. Histochem. Cytochem., 2004, 52(8), 1083-1090.
181. Sharifi, N.; Hurt, E.M.; Kawasaki, B.T.; Farrar, W.L. TGFBR3 loss and consequences in prostate cancer. Prostate, 2007, 67(3), 301-311.
182. Mathew, G.; Timm, E.A.; Jr. Sotomayor, P.; Godoy, A.; Montecinos, V.P.; Smith, G.J.; Huss, W.J. ABCG2-mediated DyeCycle Violet efflux defined side population in benign and malignant prostate. Cell Cycle, 2009, 8(7), 1053-1061.
183. Tang, D.G.; Patrawala, L.; Calhoun, T.; Bhatia, B.; Choy, G.; Schneider-Broussard, R.; Jeter, C. Prostate cancer stem/progenitor cells: Identification, characterization, and implications. Mol. Carcinog., 2007, 46(1), 1-14.
184. Wang, S.; Garcia, A.J.; Wu, M.; Lawson, D.A.; Witte, O.N.; Wu, H. Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation. Proc. Natl. Acad. Sci. USA, 2006, 103(5), 1480-1485.
185. Zhou, Z.; Flesken-Nikitin, A.; Nikitin, A.Y. Prostate cancer associated with p53 and Rb deficiency arises from the stem/progenitor cell-enriched proximal region of prostatic ducts. Cancer Res., 2007, 67(12), 5683-5690.
186. Man, Y.G.; Gardner, W.A. Focal degeneration of basal cells and the resultant auto-immunoreactions: A novel mechanism for prostate tumor progression and invasion. Med. Hypotheses, 2007, 70(2), 387-408.
187. Mimeault, M.; Pommery, N.; Henichart, J.P. New advances on prostate carcinogenesis and therapies: involvement of EGF-EGFR transduction system. Growth Factors, 2003, 21(1), 1-14.
188. Zhou, W.; Grandis, J.R.; Wells, A. STAT3 is required but not sufficient for EGF receptor-mediated migration and invasion of human prostate carcinoma cell lines. Br. J. Cancer, 2006, 95(2), 164-171.
189. Shah, R.B.; Ghosh, D.; Elder, J.T. Epidermal growth factor receptor (ErbB1) expression in prostate cancer progression: correlation with androgen independence. Prostate, 2006, 66(13), 1437-1444.
190. Rau, K.M.; Kang, H.Y.; Cha, T.L.; Miller, S.A.; Hung, M.C. The mechanisms and managements of hormone-therapy resistance in breast and prostate cancers. Endocr. Relat. Cancer, 2005, 12(3), 511-532.
191. Di Lorenzo, G.; De Placido, S. Hormone refractory prostate cancer (HRPC): present and future approaches of therapy. Int. J. Immunopathol. Pharmacol., 2006, 19(1), 11-34.
192. Winquist, E.; Waldron, T.; Berry, S.; Ernst, D.S.; Hotte, S.; Lukka, H. Non-hormonal systemic therapy in men with hormonerefractory prostate cancer and metastases: a systematic review from the Cancer Care Ontario Program in Evidence-based Care's Genitourinary Cancer Disease Site Group. BMC. Cancer, 2006, 6(1), 112.
193. van Leenders, G.J.; Aalders, T.W.; Hulsbergen-van de Kaa CA.; Ruiter, D.J.; Schalken, J.A. Expression of basal cell keratins in human prostate cancer metastases and cell lines. J. Pathol., 2001, 195(5), 563-570.
194. Sheng, T.; Li, C.; Zhang, X.; Chi, S.; He, N.; Chen, K.; McCormick, F.; Gatalica, Z.; Xie, J. Activation of the hedgehog pathway in advanced prostate cancer. Mol. Cancer, 2004, 3(1), 29.
195. Stecca, B.; Mas, C.; Altaba, A.R. Interference with HH-GLI signaling inhibits prostate cancer. Trends Mol. Med., 2005, 11(5), 199-203.
196. Datta, S.; Datta, M.W. Sonic Hedgehog signaling in advanced prostate cancer. Cell Mol. Life Sci., 2006, 63(4), 435-448.
197. Chen, B.Y.; Lin, D.P.; Liu, J.Y.; Chang, H.; Huang, P.H.; Chen, Y.L.; Chang, H.H. A mouse prostate cancer model induced by Hedgehog overexpression. J. Biomed. Sci., 2006, 13(3), 373-384.
198. Bisson, I.; Prowse, D.M. WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics. Cell Res., 2009, 19(6), 683-697.
199. Mimeault, M.; Batra, S.K. Characterization of non-malignant and malignant prostatic stem/progenitor cells by Hoecsht side population method. Methods Mol. Biol., 2009, 568, 139-149.
200. Berry, D.L.; Moinpour, C.M.; Jiang, C.S.; Ankerst, D.P.; Petrylak, D.P.; Vinson, L.V.; Lara, P.N.; Jones, S.; Taplin, M.E.; Burch, P.A.; Hussain, M.H.; Crawford, E.D. Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. J. Clin. Oncol., 2006, 24(18), 2828-2835.
201. Tannock, I.F.; de Wit, R.; Berry, W.R.; Horti, J.; Pluzanska, A.; Chi, K.N.; Oudard, S.; Theodore, C.; James, N.D.; Turesson, I.; Rosenthal, M.A.; Eisenberger, M.A. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med., 2004, 351(15), 1502-1512.
202. Calabro, F.; Sternberg, C.N. Current indications for chemotherapy in prostate cancer patients. Eur. Urol., 2007, 51(1), 17-26.
203. Gignac, G.A.; Morris, M.J.; Hussain, M. Castration resistant, taxane naive metastatic prostate cancer: Current clinical approaches and future directions. J. Urol., 2007, 178(3 Pt 2), S30-S35.
204. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Murray, T.; Thun, M.J. Cancer statistics, 2008. CA Cancer J. Clin., 2008, 58(2), 71-96.
205. Ye, X.C.; Choueiri, M.; Tu, S.M.; Lin, S.H. Biology and clinical management of prostate cancer bone metastasis. Front. Biosci., 2007, 12, 3273-3286.
206. Grubb, R.L.; III; Kibel, A.S. Prostate cancer: screening, diagnosis and management in 2007. Mol. Med., 2007, 104(5), 408-413.
207. Yuan, X.; Balk, S.P. Mechanisms mediating androgen receptor reactivation after castration. Urol. Oncol., 2009, 27(1), 36-41.
208. Petrylak, D.P.; Tangen, C.M.; Hussain, M.H.; Lara, P.N.; Jr. Jones, J.A.; Taplin, M.E.; Burch, P.A.; Berry, D.; Moinpour, C.; Kohli, M.; Benson, M.C.; Small, E.J.; Raghavan, D.; Crawford, E.D. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med., 2004, 351(15), 1513-1520.
209. Clarke, N.W. Management of the spectrum of hormone refractory prostate cancer. Eur. Urol., 2006, 50(3), 428-438.
210. Zenzmaier, C.; Untergasser, G.; Berger, P. Aging of the prostate epithelial stem/progenitor cell. Exp. Gerontol., 2008, 43(11), 981-985.
211. Gu, G.; Yuan, J.; Wills, M.; Kasper, S. Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Res., 2007, 67(10), 4807-4815.
212. Mimeault, M.; Mehta, P.P.; Hauke, R.; Batra, S.K. Functions of normal and malignant prostatic stem/progenitor cells in tissue regeneration and cancer progression and novel targeting therapies against advanced prostate cancers. Endocr. Rev., 2008, 29(2), 234-252.
213. Kurbel, S. Selective reduction of estrogen receptor (ER) positive breast cancer occurrence by estrogen receptor modulators supports etiological distinction between ER positive and ER negative breast cancers. Med. Hypotheses, 2005, 64(6), 1182-1187.
214. Rizo, A.; Vellenga, E.; de Haan G.; Schuringa, J.J. Signaling pathways in self-renewing hematopoietic and leukemic stem cells: do all stem cells need a niche? Hum. Mol. Genet., 2006, 15(Spec No 2), R210-R219.
215. de Jonge-Peeters, S.D.; Kuipers, F.; de Vries, E.G.; Vellenga, E. ABC transporter expression in hematopoietic stem cells and the role in AML drug resistance. Crit. Rev. Oncol. Hematol., 2007, 62(3), 214-226.
216. Beachy, P.A.; Karhadkar, S.S.; Berman, D.M. Tissue repair and stem cell renewal in carcinogenesis. Nature, 2004, 432(7015), 324-331.
217. Mimeault, M.; Hauke, R.; Batra, S.K. Recent advances on the molecular mechanisms involved in drug-resistance of cancer cells and novel targeting therapies. Clin. Pharmacol. Ther., 2008, 83(5), 673-691.
218. Mimeault, M.; Batra, S.K. Recent progress on tissue-resident adult stem cell biology and their therapeutic implications. Stem Cell Rev., 2008, 4(1), 27-49.
219. Kawasaki, B.T.; Hurt, E.M.; Kalathur, M.; Duhagon, M.A.; Milner, J.A.; Kim, Y.S.; Farrar, W.L. Effects of the sesquiterpene lactone parthenolide on prostate tumor-initiating cells: An integrated molecular profiling approach. Prostate, 2009, 69(8), 827-837.
220. Dubrovska, A.; Kim, S.; Salamone, R.J.; Walker, J.R.; Maira, S.M.; Garcia-Echeverria, C.; Schultz, P.G.; Reddy, V.A. The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc. Natl. Acad. Sci. USA, 2009, 106(1), 268-273.
221. Carriere, C.; Seeley, E.S.; Goetze, T.; Longnecker, D.S.; Korc, M. The Nestin progenitor lineage is the compartment of origin for pancreatic intraepithelial neoplasia. Proc. Natl. Acad. Sci. U S.A., 2007, 104(11), 4437-4442.
222. Pasca di, M.M.; Sekine, S.; Ermilov, A.; Ferris, J.; Dlugosz, A.A.; Hebrok, M. Hedgehog/Ras interactions regulate early stages of pancreatic cancer. Genes Dev., 2006, 20(22), 3161-3173.
223. Li, C.; Heidt, D.G.; Dalerba, P.; Burant, C.F.; Zhang, L.; Adsay, V.; Wicha, M.; Clarke, M.F.; Simeone, D.M. Identification of pancreatic cancer stem cells. Cancer Res., 2007, 67(3), 1030-1037.
224. Brand, R.E.; Lerch, M.M.; Rubinstein, W.S.; Neoptolemos, J.P.; Whitcomb, D.C.; Hruban, R.H.; Brentnall, T.A.; Lynch, H.T.; Canto, M.I. Advances in counselling and surveillance of patients at risk for pancreatic cancer. Gut, 2007, 56(10), 1460-1469.
225. Pasca di, M.M.; Sekine, S.; Ermilov, A.; Ferris, J.; Dlugosz, A.A.; Hebrok, M. Hedgehog/Ras interactions regulate early stages of pancreatic cancer. Genes Dev., 2006, 20(22), 3161-3173.
226. Olempska, M.; Eisenach, P.A.; Ammerpohl, O.; Ungefroren, H.; Fandrich, F.; Kalthoff, H. Detection of tumor stem cell markers in pancreatic carcinoma cell lines. Hepatobiliary Pancreat Dis. Int., 2007, 6(1), 92-97.
227. Gou, S.; Liu, T.; Wang, C.; Yin, T.; Li, K.; Yang, M.; Zhou, J. Establishment of clonal colony-forming assay for propagation of pancreatic cancer cells with stem cell properties. Pancreas, 2007, 34(4), 429-435.
228. Zhou, J.; Wang, C.Y.; Liu, T.; Wu, B.; Zhou, F.; Xiong, J.X.; Wu, H.S.; Tao, J.; Zhao, G.; Yang, M.; Gou, S.M. Persistence of side population cells with high drug efflux capacity in pancreatic cancer. World J. Gastroenterol., 2008, 14(6), 925-930.
229. Mimeault, M.; Brand, R.E.; Sasson, A.A.; Batra, S.K. Recent advances on the molecular mechanisms involved in pancreatic cancer progression and therapies. Pancreas, 2005, 31(4), 301-316.
230. Rivera, F.; Lopez-Tarruella, S.; Vega-Villegas, M.A.; Salcedo, M. Treatment of advanced pancreatic cancer: From gemcitabine single agent to combinations and targeted therapy. Cancer Treat. Rev., 2009, 35(4), 335-339.
231. El Maalouf G.; Le, T.C.; Batty, G.N.; Faivre, S.; Raymond, E. Markers involved in resistance to cytotoxics and targeted therapeutics in pancreatic cancer. Cancer Treat. Rev., 2009, 35(2), 167-174.
232. Bai, J.; Sata, N.; Nagai, H. Gene expression analysis for predicting gemcitabine sensitivity in pancreatic cancer patients. HPB (Oxford), 2007, 9(2), 150-155.
233. Hong, S.P.; Wen, J.; Bang, S.; Park, S.; Song, S.Y. CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells. Int. J. Cancer, 2009, 125(10), 2323-2331.
234. Wang, Y.H.; Li, F.; Luo, B.; Wang, X.H.; Sun, H.C.; Liu, S.; Cui, Y.Q.; Xu, X.X. A side population of cells from a human pancreatic carcinoma cell line harbors cancer stem cell characteristics. Neoplasma, 2009, 56(5), 371-378.
235. Mimeault, M.; Johansson, S.L.; Senapati, S.; Momi, N.; Chakraborty, S.; Batra, S.K. MUC4 down-regulation reverse chemoresistance of pancreatic cancer stem/progenitor cells and their progenies. Cancer Lett., 2010, (in press).
236. Ji, Q.; Hao, X.; Zhang, M.; Tang, W.; Yang, M.; Li, L.; Xiang, D.; Desano, J.T. Bommer, G.T.; Fan, D.; Fearon, E.R.; Lawrence, T.S.; Xu, L. MicroRNA miR-34 inhibits human pancreatic cancer tumorinitiating cells. PLoS ONE, 2009, 4(8), e6816.
237. Zhou, J.; Wang, C.Y.; Liu, T.; Wu, H.S.; Zhou, F.; Xiong, J.X.; Zhao, G.; Yang, M.; Yin, T.; & Zhou, M.T. Phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway is critical for survival and proliferation of pancreatic cancer stem-like side population cells. Zhonghua Yi. Xue. Za Zhi., 2008, 88(42), 2994-2998.
238. Kabashima, A.; Higuchi, H.; Takaishi, H.; Matsuzaki, Y.; Suzuki, S.; Izumiya, M.; Iizuka, H.; Sakai, G.; Hozawa, S.; Azuma, T.; Hibi, T. Side population of pancreatic cancer cells predominates in TGF-beta-mediated epithelial to mesenchymal transition and invasion. Int. J. Cancer, 2009, 124(12), 2771-2779.
239. Wang, Z.; Li, Y.; Kong, D.; Banerjee, S.; Ahmad, A.; Azmi, A.S.; Ali, S.; Abbruzzese, J.L.; Gallick, G.E.; arkar, F.H. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabineresistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res., 2009, 69(6), 2400-2407.
240. Levina, V.; Marrangoni, A.; Wang, T.; Parikh, S.; Su, Y.; Herberman, R.; Lokshin, A.; Gorelik, E. Elimination of human lung cancer stem cells through targeting of the stem cell factor-c-kit autocrine signaling loop. Cancer Res., 2009, 70(1), 338-346.
241. Calabrese, C.; Poppleton, H.; Kocak, M.; Hogg, T.L.; Fuller, C.; Hamner, B.; Oh, E.Y.; Gaber, M.W.; Finklestein, D.; Allen, M.; Frank, A.; Bayazitov, I.T.; Zakharenko, S.S.; Gajjar, A.; Davidoff, A.; Gilbertson, R.J. A perivascular niche for brain tumor stem cells. Cancer Cell, 2007, 11(1), 69-82.